arvinas_logoART_lg.jpg
Arvinas to Participate in Upcoming Investor Conferences
29 août 2024 07h00 HE | Arvinas Inc.
NEW HAVEN, Conn., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
MRTX_Logo_PrimaryBlue_4CP.jpg
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
28 août 2024 07h00 HE | Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
MRTX_Logo_PrimaryBlue_4CP.jpg
Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update
08 août 2024 07h00 HE | Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update
arvinas_logoART_lg.jpg
Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate Update
30 juil. 2024 07h00 HE | Arvinas Inc.
– Completed enrollment in the study lead-in for the VERITAC-3 Phase 3 trial in the first-line setting; continued enrollment globally in multiple clinical trials of vepdegestrant in ER+/HER2-...
MRTX_Logo_PrimaryBlue_4CP.jpg
Monte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160
27 juin 2024 07h00 HE | Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160
arvinas_logoART_lg.jpg
Arvinas Appoints Andrew Saik as Chief Financial Officer and Treasurer
24 juin 2024 16h37 HE | Arvinas Inc.
- Awards Mr. Saik an Inducement Grant in accordance with Nasdaq Listing Rule 5635(c)(4) - NEW HAVEN, Conn., June 24, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ: ARVN), a clinical-stage...
arvinas_logoART_lg.jpg
Arvinas Announces Presentations for Two of its PROTAC® Investigational Programs Targeting BCL6 and LRRK2
21 juin 2024 07h00 HE | Arvinas Inc.
– Preclinical data for ARV-393 presented at the European Hematology Association 2024 Annual Congress showed anti-tumor activity in models of B-cell lymphoma –  – Preclinical data presented at the...
Ian Taylor, Ph.D.
Arvinas Announces Promotions of Ian Taylor, Ph.D. to President of Research and Development and Angela Cacace, Ph.D. to Chief Scientific Officer
17 juin 2024 07h00 HE | Arvinas Inc.
NEW HAVEN, Conn., June 17, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation,...
MRTX_Logo_PrimaryBlue_4CP.jpg
Monte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis
14 juin 2024 08h45 HE | Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis
arvinas_logoART_lg.jpg
Arvinas to Participate in Upcoming Investor Conferences
03 juin 2024 16h30 HE | Arvinas Inc.
NEW HAVEN, Conn., June 03, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...